GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bicycle Therapeutics PLC (NAS:BCYC) » Definitions » PB Ratio

Bicycle Therapeutics (Bicycle Therapeutics) PB Ratio : 2.33 (As of Apr. 26, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Bicycle Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-26), Bicycle Therapeutics's share price is $22.94. Bicycle Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was $9.83. Hence, Bicycle Therapeutics's PB Ratio of today is 2.33.

The historical rank and industry rank for Bicycle Therapeutics's PB Ratio or its related term are showing as below:

BCYC' s PB Ratio Range Over the Past 10 Years
Min: 1.16   Med: 3.08   Max: 9.03
Current: 2.33

During the past 7 years, Bicycle Therapeutics's highest PB Ratio was 9.03. The lowest was 1.16. And the median was 3.08.

BCYC's PB Ratio is ranked better than
51.07% of 1310 companies
in the Biotechnology industry
Industry Median: 2.385 vs BCYC: 2.33

During the past 12 months, Bicycle Therapeutics's average Book Value Per Share Growth Rate was 8.50% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 29.50% per year.

During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Bicycle Therapeutics was 29.50% per year. The lowest was 20.50% per year. And the median was 25.00% per year.

Back to Basics: PB Ratio


Bicycle Therapeutics PB Ratio Historical Data

The historical data trend for Bicycle Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bicycle Therapeutics PB Ratio Chart

Bicycle Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial 1.82 3.97 5.20 3.27 1.84

Bicycle Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.27 2.63 3.55 2.05 1.84

Competitive Comparison of Bicycle Therapeutics's PB Ratio

For the Biotechnology subindustry, Bicycle Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bicycle Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bicycle Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Bicycle Therapeutics's PB Ratio falls into.



Bicycle Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Bicycle Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=22.94/9.832
=2.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Bicycle Therapeutics  (NAS:BCYC) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Bicycle Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Bicycle Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Bicycle Therapeutics (Bicycle Therapeutics) Business Description

Traded in Other Exchanges
Address
Granta Park, Great Abington, Blocks A and B, Portway Building, Cambridge, GBR, CB21 6GS
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.
Executives
Nigel Crockett officer: Chief Business Officer C/O BICYCLE THERAPEUTICS PLC, B900, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Travis Alvin Thompson officer: Chief Accounting Officer C/O BICYCLE THERAPEUTICS PLC, BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE X0 CB21 6GS
Alistair Milnes officer: Chief Operating Officer C/O BICYCLE THERAPEUTICS PLC, B900, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Kevin Lee director, officer: Chief Executive Officer C/O BICYCLE THERAPEUTICS LIMITED, B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB223AT
Nicholas Keen officer: Chief Scientific Officer C/O BICYCLE THEAPEUTICS LIMITED, B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Michael Skynner officer: Chief Operating Officer C/O BICYCLE THERAPEUTICS LIMITED, B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB223AT
Alethia Young officer: Chief Financial Officer C/O GRAPHITE BIO, INC., 201 HASKINS WAY, SUITE 210, SOUTH SAN FRANCISCO CA 94080
Lee Kalowski officer: President and CFO C/O TOKAI PHARMACEUTICALS, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Santiago Arroyo officer: Chief Development Officer C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Dominic Smethurst officer: Chief Medical Officer C/O BICYCLE THERAPEUTICS PLC, B900, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Pierre Legault director P.O. BOX 1028, C/O STONE MANAGEMENT LLC, BERWYNE PA 19312
Kate Bingham director 1365 MAIN STREET, WALTHAM MA 02451
Jose-carlos Gutierrez-ramos director C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Plc Glaxosmithkline director, 10 percent owner 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Veronica Gh Jordan director C/O ALBANY MOLECULAR RESEARCH, INC., 26 CORPORATE CIRCLE, ALBANY NY 12212-5098